Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Major Depression Disorder Clinical Trial

Official title:
Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02400346
Study type	Interventional
Source	H. Lundbeck A/S
Contact
Status	Completed
Phase	Phase 3
Start date	March 2015
Completion date	June 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02773108` - Somatic Comorbidities in Psychiatric Patients
Recruiting	`NCT05597566` - Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
Recruiting	`NCT06278038` - Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder	N/A
Recruiting	`NCT02273154` - Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder	Phase 4